Avadel Pharma (AVDL) Tops Q3 EPS by 5c

Avadel Pharma (NASDAQ: AVDL) reported Q3 EPS of ($0.03), $0.05 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $50.03 million versus the consensus estimate of $48.44 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Barclays Upgrades 1&1 AG (1U1:GR) to Overweight
• Micron Technology (MU) PT Raised to $1,280 at Baird
• Blackberry earnings preview Q1: strong print expected, AI potential in focus